Dmitry Balyasny’s Design Therapeutics DSGN Stock Holding History

Dmitry Balyasny’s Portfolio DSGN Stock Details DSGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.61M	Buy	+111,103	New	+$1.39M	﹤0.01%	1938
2023 Q3	–	Sell	-18,499	Closed	-$117K	–	2359
2023 Q2	$117K	Buy	+18,499	New	+$113K	﹤0.01%	2110
2022 Q4	–	Sell	-11,134	Closed	-$186K	–	2877
2022 Q3	$186K	Buy	+11,134	New	+$222K	﹤0.01%	2321
2021 Q2	–	Sell	-43,250	Closed	-$1.29M	–	2048
2021 Q1	$1.29M	Buy	+43,250	New	+$1.46M	0.01%	1167

Other funds holding DSGN

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dmitry Balyasny's DSGN Position: Q2 2026 in Review

Dmitry Balyasny opened a new position in Design Therapeutics (DSGN) in Q2 2026: 111,103 shares worth $1.61M. The stake represents ﹤0.01% of the portfolio and ranks #1938 among its holdings. This is a return to the name: Dmitry Balyasny previously reported a position in DSGN as recently as Q2 2023.

Dmitry Balyasny first reported a position in DSGN in Q1 2021 and has held it in 4 quarters since. 136 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

Dmitry Balyasny held 111,103 shares of Design Therapeutics worth $1.61M as of Q2 2026.
Design Therapeutics was a new Dmitry Balyasny position in Q2 2026.
Design Therapeutics made up ﹤0.01% of Dmitry Balyasny's portfolio in Q2 2026, its #1938 holding.
Dmitry Balyasny first reported a position in Design Therapeutics in Q1 2021 and has held it in 4 quarters since.
136 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.